Citations

Showing 10 of 108083 citations.

Real‐world incidence of efficacy and safety outcomes in patients on direct oral anticoagulants with left ventricular systolic dysfunction at a tertiary referral center
Tseng, Andrew S. , Shen, Win‐Kuang , McBane, Robert D. , Mankad, Sunil , Esser, Heidi, Vucicevic, D., Shamoun, Fadi , Shamoun, Fadi E., Tseng, A S , McBane, Robert , Schleifer, J. William

Mayo Clinic

Clinical Cardiology | December 16, 2017 | Volume: 40 | Issue: 12 | Pages: 1328-1332

10.1002/clc.22833 | PMID 29247519 Get It

BackgroundPatients with heart failure (HF) have increased risk for thromboembolic events. Real‐world incidences of efficacy and safety outcomes of direct oral anticoagulants (DOACs) in patients with left ventricular systolic dysfunction (LVSD) are of growing clinical interest.HypothesisReal‐world efficacy and safety outcomes of DOACs in patients with LVSD will be similar to those of LVSD or HF subgroups in the RE‐LY, ROCKET‐AF, and ARISTOTLE trials.MethodsWe performed a retrospective review of adult patients with LVSD (left ventricular ejection fraction ≤40%) on DOAC therapy between 2010 and 2016. Incidences of safety and efficacy outcomes of anticoagulation with DOACs were extracted from primary and secondary hospital discharge diagnoses.ResultsDOACs were prescribed to 287 patients with LVSD over a mean follow‐up of 313.3 ± 52.3 days. Many patients had moderate and severe chronic kidney disease (28.9% and 10.1%, respectively) and indications for anticoagulation therapy other than atrial fibrillation (19.9%). For efficacy outcomes, the calculated incidence rates of ischemic stroke and systemic embolism were 1.2 (95% confidence interval [CI]: 0.25‐3.56) and 0.81 (95% CI: 0.10‐2.94) events per 100 person‐years, respectively. For the safety outcomes, incidence rates of GI bleeding and intracranial hemorrhage were 2.4 (95% CI: 0.8‐5.3) and 0.41 (95% CI: 0.1‐2.2) events per 100 patient‐years, respectively.ConclusionsOur findings are largely compatible with the results of LVSD or HF subgroups in RE‐LY, ROCKET‐AF, and ARISTOTLE trials and add to increasing confidence that DOACs can be safely used for stroke and systemic embolism prevention in patients with LVSD.
Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis
Ali, Ahmad H. , Tabibian, James H. , Nasser‐Ghodsi, Navine , Lennon, Ryan J. , DeLeon, Thomas, Hilscher, Moira , Silveira, Marina G., Carey, Elizabeth J. , Lindor, Keith D. , Ali, Ahmad Hassan, Borad, Mitesh J. , Tabibian, James H

Mayo Clinic

Hepatology | December 16, 2017 | Volume: 67 | Issue: 6 | Pages: 2338-2351

10.1002/hep.29730 | PMID 29244227 Get It

Primary sclerosing cholangitis (PSC) is a risk factor for cholangiocarcinoma (CCA) and gallbladder carcinoma (GBCa). Surveillance for GBCa is recommended, but the clinical utility of surveillance for other hepatobiliary cancers (HBCa) in PSC, namely CCA and hepatocellular carcinoma (HCC), remains unclear. We aimed to determine whether surveillance is associated with better survival after diagnosis of HBCa in patients with PSC. Medical records of PSC patients seen at the Mayo Clinic Rochester from 1995 to 2015 were reviewed. Patients were included if they had ≥1 year of follow‐up and developed HBCa. Patients were categorized according to their surveillance status (abdominal imaging, carbohydrate antigen 19‐9, and alpha‐fetoprotein). The primary endpoints were HBCa recurrence, HBCa‐related death, and all‐cause mortality. Overall survival was assessed by the Kaplan‐Meier survival method; HBCa‐related survival was assessed using competing risk regression. Tests of significance were two‐tailed, and a P value <0.05 was considered statistically significant. From 1995 to 2015, a total of 79 of 830 PSC patients were diagnosed with HBCa. Cumulative follow‐up was 712 and 283 person‐years pre‐ and post‐HBCa diagnosis, respectively. Seventy‐eight percent of patients (54/79) developed CCA, 21% (17/79) HCC, 6% (5/79) GBCa, 3% (2/79) both CCA and HCC, and 1% (1/79) both HCC and GBCa. Fifty‐one percent (40/79) were under HBCa surveillance, and 49% (39/79) were not. Patients in the surveillance group had significantly higher 5‐year overall survival (68% versus 20%, respectively; P < 0.001) and significantly lower 5‐year probability of experiencing an HBCa‐related adverse event (32% versus 75%, respectively; P < 0.001) compared with the no‐surveillance group. Conclusion: This study demonstrates that HBCa surveillance significantly improves outcomes, including survival, in patients with PSC. (Hepatology 2018;67:2338‐2351).
Obesity‐induced mitochondrial dysfunction in porcine adipose tissue‐derived mesenchymal stem cells
Eirin, Alfonso , Zhu, Xiangyang , Chanana, Pritha , Wijnen, André J. van , Lerman, Lilach O. , Meng, Yu , Lerman, Lilach O , van Wijnen, Andre J , Eirin, Alfonso , Tang, Hui Ru , Lerman, Amir

Mayo Clinic

Journal of Cellular Physiology | December 16, 2017 | Volume: 233 | Issue: 8 | Pages: 5926-5936

10.1002/jcp.26402 | PMID 29243809 Get It

Transplantation of autologous mesenchymal stem cells (MSCs) may be a viable option for treatment of several diseases. MSCs efficacy depends on adequate function of their mitochondria, which might be impaired in a noxious milieu. We hypothesized that obesity compromises MSCs mitochondrial structure and function, possibly via micro‐RNA (miRNA)‐based mechanisms. MSCs were collected from swine abdominal adipose tissue after 16 weeks of Lean or Obese diet (n = 7 each). Mitochondrial structure was assessed by electron microscopy and function by membrane potential and cytochrome‐c oxidase (COX)‐IV activity. Oxidative stress was assessed by Mito‐SOX and dihydroethidium staining. Next‐generation sequencing (RNA‐seq) was performed to identify miRNAs expression in MSCs, and predicted mitochondrial target genes were then identified (MitoCarta). Compared to Lean‐MSCs, mitochondria from Obese‐MSCs were smaller and showed cristae remodeling and loss. Mitochondrial membrane potential and COX‐IV activity decreased in Obese‐MSCs, associated with increased mitochondrial oxidative stress. RNA‐seq generated reads for 413 miRNAs, of which 5 miRNAs were upregulated in Obese‐MSCs (fold change >2, p < 0.05) and found to target 43 specific mitochondrial genes. Obesity impairs MSC mitochondrial structure and function, possibly mediated partly through miRNA‐induced mitochondrial gene regulation, leading to increased oxidative stress. Importantly, these alterations may limit the therapeutic use of autologous MSCs in subjects with obesity.
Association between atopic dermatitis and squamous cell carcinoma: a case–control study
Cho, Janice , Wetter, David A. , Bartley, Adam C. , Brewer, Jerry D., Cho, Janice M, Davis, Dawn Marie R.

Mayo Clinic

International Journal of Dermatology | December 16, 2017 | Volume: 57 | Issue: 3 | Pages: 313-316

10.1111/ijd.13857 | PMID 29243817 Get It

AbstractBackgroundConflicting data have been published on whether an association exists between atopic dermatitis (AD) and nonmelanoma skin cancer. This study aimed to determine whether individuals with AD had an increased risk of squamous cell carcinoma (SCC) development.MethodsWe conducted a retrospective, case–control study of patients residing in Olmsted County, Minnesota. Cases were selected from patients seen at Mayo Clinic (Rochester, Minnesota) who had an initial SCC diagnosis (either invasive SCC or SCC in situ) from January 1, 1996, through December 23, 2010. Age‐ and sex‐matched controls were selected from patients seen at Mayo Clinic with no history of SCC before the case event date.ResultsThree hundred ninety‐nine individuals with a documented history of SCC were identified and matched with 780 controls who did not have a history of SCC. After adjusting for race, smoking history, ionizing radiation exposure, corticosteroid and cyclosporine use, and non‐SCC skin cancers, the odds ratio for SCC development between patients with history of AD versus patients without history of AD was 1.75 (95% CI, 1.05–2.93).ConclusionsOur findings support an increased risk of SCC development in the setting of AD.
Surfacing and addressing hospitalized patients’ needs: Proactive nurse rounding as a tool
Danaf, Jad Al, Chang, Bickey H. , Shaear, Mohammad , Johnson, Kristine M., Miller, Sandra, Nester, Lynda, Williams, Amy W. , Aboumatar, Hanan

Mayo Clinic

Journal of Nursing Management | December 16, 2017 | Volume: 26 | Issue: 5 | Pages: 540-547

10.1111/jonm.12580 | PMID 29243363 Get It

Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies
Shen, Jiayin , Hu, Yingwen, Putt, Karson S. , Han, Haiyong , Visscher, Daniel W., Murphy, Linda M., Singhal, Sunil Kumar , Low, Philip S.

Mayo Clinic

Oncotarget | December 16, 2017 | Volume: 9 | Issue: 4 | Pages: 4485-4495

10.18632/oncotarget.23321 | PMID 29435118 Get It

Hospital-Based Clinicians’ Perceptions of Geographic Cohorting: Identifying Opportunities for Improvement
Johnson, Cynthia S. , Hui, Siu L., Kashiwagi, Deanne T. , Kashiwagi, Deanne, Kara, Areeba

Mayo Clinic

American Journal of Medical Quality | December 16, 2017 | Volume: 33 | Issue: 3 | Pages: 303-312

10.1177/1062860617745123 | PMID 29241347 Get It

Members of the Society of Hospital Medicine were surveyed about geographic cohorting (GCh); 369 responses were analyzed, two thirds of which were from GCh participants. Improved collaboration with the bedside nurse, increased nonclinical interactions, decreased paging interruptions, and improved efficiency were perceived by >50%. Narrowed clinical expertise, increased fragmentation, increased face-to-face interruptions, and an adverse impact on camaraderie within the hospitalist group were reported by 25% to 50%. Academic practices were associated with positive perceptions while higher patient loads were associated with negative perceptions. Comments on GCh benefits invoked improvements in (1) interprofessional collaboration, (2) efficiency, (3) patient-centeredness, (4) nursing satisfaction, and (5) GCh mediated facilitation of other interventions. GCh downsides included (1) professional and personal dissatisfaction, (2) concerns about providing suboptimal care, and (3) implementation barriers. GCh is receiving attention. Although it facilitates important benefits, it is perceived to mediate unintended consequences, which should be addressed in redesign efforts.
A noncoding variant in GANAB explains isolated polycystic liver disease (PCLD) in a large family
Besse, Whitney , Choi, Jungmin , Ahram, Dina , Mane, Shrikant , Sanna‐Cherchi, Simone , Torres, Vicente E. , Somlo, Stefan , Torres, Vicente E

Mayo Clinic

Human Mutation | December 16, 2017 | Volume: 39 | Issue: 3 | Pages: 378-382

10.1002/humu.23383 | PMID 29243290 Get It

First‐Line Antiarrhythmic Transplacental Treatment for Fetal Tachyarrhythmia: A Systematic Review and Meta‐Analysis
Baskar, Shankar , Alahdab, Fares , Czosek, Richard J. , Murad, M. Hassan , Divanović, Allison , Murad, Mohammad Hassan, Murad, M Hassan , Alsaied, Tarek , Fares, Munes , Prokop, Larry J. , Alahdab, Fares

Mayo Clinic

Journal of the American Heart Association | December 16, 2017 | Volume: 6 | Issue: 12 | Pages: No page available

10.1161/jaha.117.007164 | PMID 29246961 Get It

Background There is no consensus on the most effective and best tolerated first‐line antiarrhythmic treatment for fetal tachyarrhythmia. The purpose of this systematic review and meta‐analysis was to compare the efficacy, safety, and fetal–maternal tolerance of first‐line monotherapies for fetal supraventricular tachycardia and atrial flutter. Methods and Results A comprehensive search of several databases was conducted through January 2017. Only studies that made a direct comparison between first‐line treatments of fetal tachyarrhythmia were included. Outcomes of interest were termination of fetal tachyarrhythmia, fetal demise, and maternal complications. Ten studies met inclusion criteria, with 537 patients. Overall, 291 patients were treated with digoxin, 137 with flecainide, 102 with sotalol, and 7 with amiodarone. Digoxin achieved a lower rate of supraventricular tachycardia termination compared with flecainide (odds ratio [ OR ]: 0.773; 95% confidence interval [ CI ], 0.605–0.987; I 2 =34%). In fetuses with hydrops fetalis, digoxin had lower rates of tachycardia termination compared with flecainide ( OR : 0.412; 95% CI , 0.268–0.632; I 2 =0%). There was no significant difference in the incidence of maternal side effects between digoxin and flecainide groups ( OR : 1.134; 95% CI , 0.129–9.935; I 2 =80.79%). The incidence of maternal side effects was higher in patients treated with digoxin compared with sotalol ( OR : 3.148; 95% CI , 1.468–6.751; I 2 =0%). There was no difference in fetal demise between flecainide and digoxin ( OR : 0.767; 95% CI , 0.140–4.197; I 2 =44%). Conclusions Flecainide may be more effective treatment than digoxin as a first‐line treatment for fetal supraventricular tachycardia.
Successful Percutaneous Mitral Paravalvular Leak Closure Is Associated With Improved Midterm Survival
Zack, Chad, Sarraf, Mohammad , Eleid, Mackram F. , Reeder, Guy S., Hagler, Donald J. , Maalouf, Joseph F., Rihal, Charanjit S. , Zack, Chad J, Cabalka, Allison K. , Alkhouli, Mohamad , Nkomo, Vuyisile T. , Rihal, Charanjit S.

Mayo Clinic

Circulation: Cardiovascular Interventions | December 16, 2017 | Volume: 10 | Issue: 12 | Pages: No page available

10.1161/circinterventions.117.005730 | PMID 29246914 Get It

Background— Percutaneous closure of prosthetic mitral valve paravalvular leak (PVL) has emerged as an alternative to surgical treatment in high-risk patients. Limited data exist on the impact of successful percutaneous PVL closure on midterm outcomes. Methods and Results— We examined consecutive patients who underwent percutaneous mitral PVL closure at Mayo Clinic, Rochester, MN, between January 2006 and January 2017. Procedural success, in-hospital outcomes, and midterm mortality were assessed. A total of 231 patients underwent percutaneous mitral PVL repair at a mean age of 67±12 years. Mean time from mitral valve replacement to percutaneous PVL repair was 1.25 (0.31–7.25) years. One hundred sixty-two patients (70%) had ≤mild PVL after the procedure. Compared with those who had >mild residual PVL, patients with ≤mild residual PVL had lower rates of repeat surgical interventions (6% versus 17%; P =0.004) and lower all-cause mortality at 30 days (1% versus 14%; P <0.001) and 1 year (15% versus 39%; P <0.001). Survival at 3 years was 61% in patients who had ≤mild residual leak and 47% in patients with higher grade of residual PVL ( P =0.002). Conclusions— In a large consecutive cohort of patients undergoing percutaneous mitral PVL closure, successful percutaneous reduction of the PVL to mild or less was associated with significant midterm survival benefit.